Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,730 recruiting studies in this area right now.
By phase
- Not applicable9,856
- Phase 24,487
- Phase 12,738
- Phase 1/Phase 21,696
- Phase 31,409
- Phase 2/Phase 3281
- Phase 4263
Top conditions
- Breast Cancer1,233
- Prostate Cancer660
- Cancer655
- Colorectal Cancer499
- Lung Cancer430
- Ovarian Cancer341
- Multiple Myeloma330
- Gastric Cancer302
- Pancreatic Cancer295
- Acute Myeloid Leukemia290
- Hepatocellular Carcinoma285
- Solid Tumor256
- Advanced Solid Tumor254
- Cervical Cancer233
- Head and Neck Cancer229
- Endometrial Cancer207
- Advanced Solid Tumors196
- Esophageal Cancer196
Leading sponsors
- M.D. Anderson Cancer Center452
- Fudan University317
- National Cancer Institute (NCI)291
- Sun Yat-sen University290
- Memorial Sloan Kettering Cancer Center289
- Mayo Clinic237
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center146
- AstraZeneca131
- University Health Network, Toronto125
Where studies are running
- California1,432
- Texas644
- Arizona514
- Florida437
- Alabama419
- New York410
- Massachusetts342
- Maryland331
- New Jersey267
- Pennsylvania237
Recruiting studies20,730 total
- NCT06508567Recruiting
MRI-Guided Internal Radiation for Returning Prostate Cancer
This trial tests a new way to use a type of internal radiation (high-dose-rate brachytherapy) guided by MRI to treat prostate cancer that has come back in the same area after previous radiation therapy. It is designed to be more precise and hopefully safer while using the latest PSMA PET scans to make sure the cancer hasn't spread.
Toronto, OntarioAges 18 years+ - NCT06508775Recruiting
Long-term checkup for Miltenyi cell therapy patients
This study is a long-term check-in for people who received a special type of immunotherapy (CAR T cells) made by Miltenyi. It helps researchers see how you're doing over time after your treatment.
BerlinAges Any age - NCT06508983RecruitingPhase 3
SG301 for multiple myeloma returning after treatment
This trial tests a new drug called SG301 added to standard treatments (pomalidomide and dexamethasone) for people with multiple myeloma that came back or got worse after prior therapy. It may help if you have tried lenalidomide and a proteasome inhibitor but your cancer is still active.
Beijing, Beijing MunicipalityAges 18–75 - NCT06508931RecruitingPhase 2
Zamtocabtagene autoleucel for children with B-cell lymphoma or leukemia
This trial tests a new CAR T-cell therapy (zamtocabtagene autoleucel) for children and teens whose B-cell lymphoma or leukemia has come back or hasn't responded to other treatments. The goal is to see if this one-time infusion can help their immune system fight the cancer.
Paris, Boulevard Sérurier 48Ages 6 months–17 years - NCT06509009RecruitingPhase 2
Nimotuzumab and TGP for first-line recurrent / metastatic nasopharyngeal cancer
This trial tests a combination of two drugs—nimotuzumab (a targeted therapy) and TGP (a chemotherapy)—as a first treatment for people whose nasopharyngeal cancer has returned or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
Beijing, Beijing MunicipalityAges 18–75 - NCT06509126RecruitingPhase 3
Panitumumab with Chemo: Continuous or Intermittent for Advanced CRC
This trial compares giving panitumumab plus FOLFIRI (two chemotherapy drugs) either continuously or with breaks, as a first treatment for left-sided colorectal cancer that has spread. It's for people whose tumors have certain genetic markers (RAS/BRAF wild-type) and haven't had treatments for advanced disease before.
NaplesAges 18–100 - NCT06509568RecruitingPhase 2
Chemoradiation plus immunotherapy before surgery for esophageal cancer
This trial tests giving a combination of chemotherapy, radiation therapy, and an immunotherapy drug before surgery for a type of esophageal cancer (squamous cell). The goal is to see if this approach helps shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
Hangzhou, ZhejiangAges 18–75 - NCT06509724RecruitingPhase 3
Comparing standard vs. shorter radiation after hysterectomy for cervical cancer
This trial tests two different radiation schedules for women with high-risk cervical cancer after surgery. The goal is to see if a shorter course of radiation works as well as or better than the standard longer course, while possibly being more convenient.
Seoul, Gangnam-guAges 20–75 - NCT06509945Recruiting
Donor stem cell transplant for high-risk T-cell lymphoma
This trial tests giving a donor stem cell transplant (called allo-PBSCT) as the first treatment after chemotherapy for people with high-risk peripheral T-cell lymphoma. It may help prevent the lymphoma from coming back.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06510309RecruitingPhase 2
Rituximab plus venetoclax for untreated marginal zone lymphoma
This trial tests a combination of two drugs, rituximab and venetoclax, as a first treatment for marginal zone lymphoma that has not been treated before. The goal is to see if this drug pair is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT06510283RecruitingPhase 2
Taitacept for refractory or recurrent autoimmune encephalitis
This trial tests a new drug called Taitacept for people with autoimmune encephalitis (brain inflammation caused by the immune system) that has not improved with standard treatments or has returned. The goal is to see if Taitacept can help control symptoms.
Beijing, Beijing MunicipalityAges 14 years+ - NCT06510361RecruitingPhase 2
Epcoritamab for follicular lymphoma not cured by initial treatment
This trial tests a drug called epcoritamab for people with follicular lymphoma (a type of slow-growing blood cancer) that improved but did not completely go away after standard first therapy. The goal is to see if epcoritamab can help achieve a complete remission.
Stanford, CaliforniaAges 18 years+ - NCT06510491RecruitingPhase 2
Epcoritamab for relapsed Waldenstrom macroglobulinemia
This trial tests epcoritamab, an immunotherapy that helps your immune system attack cancer cells, for people with Waldenstrom macroglobulinemia (WM) whose disease has gotten worse or who couldn't tolerate previous treatments. It's for those who've already tried a BTK inhibitor (like ibrutinib or zanubrutinib) and an anti-CD20 antibody (like rituximab).
Boston, MassachusettsAges 18 years+ - NCT06510543Recruiting
Nutrition drink before and after esophageal cancer surgery
This study tests a special nutrition drink (ORAL IMPACT®) before and after esophageal cancer surgery. It aims to help patients who are malnourished get stronger and recover better.
Beijing, Beijing MunicipalityAges 18–80 - NCT06510660RecruitingPhase 2
Immunotherapy and Chemoradiation for Advanced Esophageal Cancer
This trial tests a combination of immunotherapy (adebrelimab) plus standard chemotherapy and radiation for people with advanced esophageal cancer that cannot be removed by surgery. The goal is to see if adding the immunotherapy before and during chemoradiation helps control the cancer better.
Fuzhou, FujianAges 18–70 - NCT06510699RecruitingPhase 2
Genetics to improve fungal infection treatment
This trial tests if using genetic information can help doctors choose the right dose of the antifungal drug voriconazole. It aims to improve treatment and reduce side effects for people with fungal infections.
Seattle, WashingtonAges 2 years+ - NCT06510868Recruiting
MDS risk study for NET patients before or after PRRT
This study looks at the risk of developing Myelodysplastic Syndrome (MDS), a blood disorder, in people with Neuroendocrine Tumors (NET) who are treated with Peptide Radionuclide Therapy (PRRT). It involves a simple blood test to check for genetic changes linked to MDS. Participating can help understand and potentially prevent this side effect.
Toronto, OntarioAges Any age - NCT06511037RecruitingEarly Phase 1
Dye injection to help see cancer during belly surgery
This study tests a special dye, called pafolacianine, that is injected before surgery to help surgeons see hidden cancer spots in the belly during the operation. The goal is to see if using this dye improves how completely the cancer is removed in people with gastrointestinal cancer that has spread to the belly lining.
Orange, CaliforniaAges 18 years+ - NCT06511518Recruiting
Talking therapy for fatigue in advanced cancer
This study tests whether cognitive behavioral therapy, a type of talking therapy, can help reduce severe fatigue in people with advanced solid tumors or gliomas who are receiving or have completed palliative treatment. The goal is to see if this approach improves energy levels and quality of life.
Amsterdam, North HollandAges 18 years+ - NCT06511648RecruitingPhase 2
Erdafitinib with or without immunotherapy for FGFR-altered bladder cancer
This trial tests a targeted therapy called erdafitinib, either alone or combined with an immunotherapy drug (cetrelimab), for people with muscle-invasive bladder cancer that has a specific FGFR gene change. It may be an option if you cannot take cisplatin chemotherapy and have not had prior treatment for this cancer.
Clermont-FerrandAges 18 years+ - NCT06511674Recruiting
Nerve pain risk study for cancer patients
This study looks at why some people with cancer develop nerve pain (neuropathic pain) during treatment. By tracking your health and symptoms, researchers hope to find ways to predict and prevent this side effect.
AjaccioAges 18 years+ - NCT06511882RecruitingPhase 2
Stopping AML treatment after reaching remission with no detectable disease
This trial tests whether it is safe to stop taking a type of chemotherapy (azacitidine or decitabine) combined with venetoclax if you have acute myeloid leukemia (AML) and have achieved a remission with no trace of leukemia cells. If you have been on this treatment for less than a year and are not eligible for a stem cell transplant, you may be able to stop therapy and be monitored closely.
Tampa, FloridaAges 18 years+ - NCT06512311Recruiting
Personalized drug testing for newly diagnosed glioblastoma
This trial tests whether testing drugs on your tumor cells in a lab can help find the best treatment for you. It is for people with a specific type of glioblastoma that has not been treated yet.
Vienna, State of ViennaAges 18–75 - NCT06512051RecruitingPhase 1/Phase 2
Study of SHR-A2102 and Adebrelimab for advanced lung cancer
This trial tests a combination of two drugs, SHR-A2102 and Adebrelimab, with or without other treatments, for people with advanced or metastatic non-small cell lung cancer that cannot be removed by surgery or cured with radiation. It aims to see if this approach can shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–70
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,730 recruiting oncology studies from the U.S. registry right now, out of 32,266 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.